Brian G. M. Durie
#115,898
Most Influential Person Now
Brian G. M. Durie's AcademicInfluence.com Rankings
Brian G. M. Duriemedical Degrees
Medical
#1664
World Rank
#2028
Historical Rank
Hematology
#20
World Rank
#23
Historical Rank
Download Badge
Medical
Why Is Brian G. M. Durie Influential?
(Suggest an Edit or Addition)Brian G. M. Durie's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival (1975) (2956)
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) (2949)
- Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
- International staging system for multiple myeloma. (2005) (1929)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. (2015) (1274)
- Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. (1978) (1035)
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (2011) (862)
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008) (764)
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009) (718)
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial (2017) (585)
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. (2016) (582)
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) (532)
- Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. (2006) (494)
- Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. (2003) (445)
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma (2017) (419)
- Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma (2005) (402)
- Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. (1987) (372)
- Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. (2010) (365)
- Modulation of multidrug-resistant multiple myeloma by cyclosporin (1992) (334)
- Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. (2017) (320)
- International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. (2014) (318)
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. (2011) (313)
- C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. (1992) (310)
- International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. (2013) (309)
- Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. (1986) (309)
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. (2011) (295)
- Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. (2015) (293)
- Whole-body (18)F-FDG PET identifies high-risk myeloma. (2002) (285)
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. (2018) (279)
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. (2016) (277)
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (2018) (266)
- Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. (2018) (263)
- The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. (2006) (259)
- Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19) (1990) (237)
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study (2016) (235)
- Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. (1980) (234)
- Management of treatment-emergent peripheral neuropathy in multiple myeloma (2012) (229)
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. (2009) (220)
- Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. (2010) (214)
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. (2019) (213)
- New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) (2014) (211)
- Staging and kinetics of multiple myeloma. (1982) (206)
- International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
- Polyamines as markers of response and disease activity in cancer chemotherapy. (1977) (200)
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. (2015) (199)
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. (2008) (198)
- IMWG consensus on maintenance therapy in multiple myeloma. (2012) (191)
- Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer (1975) (190)
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group (2016) (189)
- Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). (2010) (188)
- Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). (1990) (187)
- Osteonecrosis of the jaw and bisphosphonates. (2005) (185)
- International Myeloma Working Group recommendations for global myeloma care (2014) (183)
- Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy (2007) (183)
- Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. (1983) (176)
- CALLA-positive myeloma: an aggressive subtype with poor survival. (1985) (151)
- Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. (2010) (149)
- International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation (2009) (143)
- Survival and years of life lost in different age cohorts of patients with multiple myeloma. (2010) (142)
- High speed scintillation autoradiography (1975) (140)
- Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. (1983) (140)
- Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. (2006) (135)
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
- Effects of cloned human leukocyte interferons in the human tumor stem cell assay. (1983) (130)
- Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. (2004) (121)
- Comparison of bone scintigraphy and radiography in multiple myeloma. (1980) (119)
- Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group (2017) (112)
- A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience (2003) (112)
- Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features (1987) (105)
- Management of multiple myeloma: a systematic review and critical appraisal of published studies. (2003) (102)
- Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. (2011) (102)
- Reversal of drug‐resistance in multiple myeloma with verapamil (1988) (101)
- Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy (1984) (91)
- International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) (2020) (89)
- Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232. (2007) (88)
- Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. (1982) (87)
- Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study (2014) (84)
- Myelomonocytic Antigen Positive Multiple Myeloma (1989) (83)
- Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration. (1983) (80)
- Clinical correlations of in vitro drug sensitivity. (1980) (80)
- Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) (2020) (79)
- The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group (2010) (79)
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
- MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. (2017) (77)
- Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives (2015) (76)
- Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. (1984) (73)
- Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. (2008) (71)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2016) (69)
- Clinical correlations of drug sensitivity in the human tumor stem cell assay. (1980) (66)
- Staging and kinetics of multiple myeloma. (1982) (65)
- Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project (2018) (64)
- The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement (2008) (63)
- Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 (2015) (62)
- Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC) (2018) (62)
- Cellular and molecular genetic features of myeloma and related disorders. (1992) (62)
- Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival (2008) (60)
- Establishment of two new myeloma cell lines from bilateral pleural effusions: evidence for sequential in vivo clonal change. (1985) (58)
- Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma (2009) (58)
- Cellular kinetics in multiple myeloma. A new approach to staging and treatment. (1975) (57)
- Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. (2021) (56)
- Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA‐NCI roundtable symposium (2014) (55)
- Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. (2021) (54)
- Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. (2007) (52)
- Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. (2019) (48)
- Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group (2018) (48)
- Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis (2015) (46)
- Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma (2013) (46)
- The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) (2019) (45)
- Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report (2021) (44)
- Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment (2020) (43)
- Analysis of multidrug‐resistance (MDR‐1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma (1993) (43)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2018) (42)
- Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. (1976) (42)
- Low-dose thalidomide in myeloma: efficacy and biologic significance. (2002) (42)
- Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma (2010) (41)
- Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features. (1987) (40)
- Kinetics of circulating B lymphocytes in human myeloma. (1983) (40)
- Tumor growth stimulation in vitro by interferons. (1983) (39)
- Spontaneous secretion of tumor necrosis factor‐beta by human myeloma cell lines (1989) (39)
- Role of surgical treatment in the management of complications of the gastrointestinal tract in patients with leukemia. (1987) (39)
- Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma. (2006) (38)
- Management of multiple myeloma in Asia: resource-stratified guidelines. (2013) (37)
- A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results (2008) (35)
- A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma (2012) (35)
- Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival. (2010) (35)
- Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies (2021) (34)
- Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211 (2015) (34)
- New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. (2005) (34)
- Myelomonocytic antigen positive multiple myeloma. (1989) (32)
- The current status and future prospects of treatment for multiple myeloma. (1982) (32)
- Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage (2021) (32)
- Clarification of the definition of complete response in multiple myeloma (2015) (32)
- Osteonecrosis of the Jaws in Myeloma: Time Dependent Correlation with Aredia® and Zometa® Use. (2004) (31)
- Total cost comparison in relapsed/refractory multiple myeloma (2013) (30)
- Myelomonocytic myeloma cell line (LB 84-1). (1989) (30)
- T-cell antigen-positive multiple myeloma. (1990) (29)
- High Incidence of Thrombotic Events Observed in Patients Receiving Lenalidomide (L) + Dexamethasone (D) (LD) as First-Line Therapy for Multiple Myeloma (MM) without Aspirin (ASA) Prophylaxis. (2005) (28)
- Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. (2015) (28)
- Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy (2004) (28)
- Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) (2018) (28)
- Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry (2018) (27)
- Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. (1977) (27)
- In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations. (1982) (26)
- Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). (2009) (26)
- Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma. (2005) (26)
- Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study. (2009) (26)
- Heterogeneity of Second‐Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010–2016) (2018) (25)
- A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma (2007) (25)
- Interaction of allopurinol with 6-mercaptopurine and azathioprine. (1982) (25)
- Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. (2018) (25)
- Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211). (2020) (24)
- Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. (2019) (22)
- The epidemiology of multiple myeloma. (2001) (22)
- Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide (2016) (21)
- End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma (2017) (21)
- SPONTANEOUS EVOLUTION OF IMMUNE COMPETENCE IN DIGEORGE SYNDROME (1974) (21)
- Cytogenetic analysis of leukaemic colonies from acute and chronic myelogenous leukaemia. (1983) (20)
- Indium-111 bleomycin tumor scanning in lymphoma. (1975) (19)
- Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma (2009) (19)
- The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement (2008) (19)
- Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. (2019) (18)
- A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis (2014) (18)
- Cellular kinetics staging, and immunoglobulin synthesis in multiple myeloma. (1975) (18)
- Interferon alfa-2b-cyclophosphamide combination studies: in vitro and phase I-II clinical results. (1986) (18)
- Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312) (2004) (17)
- Treatment of myeloma--are we making progress? (2008) (17)
- Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies. (1987) (17)
- Immunoquantitation of free light chain immunoglobulins: applications in multiple myeloma. (1978) (16)
- Metabolism of [14C]spermidine and [14C]putrescine in normal volunteers and in cancer patients. (1978) (16)
- Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma. (2009) (16)
- Phagocytic, lambda light chain, plasma cell myeloma. (1983) (16)
- Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. (2012) (16)
- Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. (2019) (16)
- Cytogenetic and clinical assessment of six patients with erythroleukemia. (1983) (15)
- Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma (2020) (15)
- Macrophages as an important source of paracrine IL6 in myeloma bone marrow. (1990) (15)
- Aggressive phase of multiple myeloma with pulmonary cell infiltrates. (1982) (14)
- Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry (2016) (14)
- Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop (2018) (14)
- The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. (2013) (14)
- Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. (2017) (14)
- Myeloma and related disorders. (1994) (14)
- Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients (2011) (14)
- Effect of danazol on coagulation parameters and bleeding in hemophilia. (1985) (13)
- A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808) (2020) (13)
- Myeloma bone marrow acid phosphatase staining: a correlative study of 38 patients (1980) (13)
- The biology of multiple myeloma (1988) (13)
- Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients. (2009) (13)
- Prognostic factors and staging systems for multiple myeloma: Comparisons between the medical research council studies in the United Kingdom and the Southwest oncology group studies in the United States (1988) (13)
- Meaningful endpoints for therapies approved for hematologic malignancies (2017) (12)
- Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN) (2020) (12)
- Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group (2016) (12)
- Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis (2020) (11)
- An International, Randomized, Double Blind Trial Comparing Denosumab With Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) With Newly Diagnosed Multiple Myeloma (2017) (11)
- Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. (2018) (11)
- Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry (2019) (10)
- Low circulating T‐helper cells in relapsing multiple myeloma (1989) (10)
- PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG ) (2014) (10)
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data (2020) (10)
- Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma (2019) (10)
- Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma (2020) (10)
- Cytogenetic Abnormalities in Multiple Myeloma (1991) (9)
- Prophylaxis against leptospirosis with doxycycline. (1984) (9)
- Connect MM Registry as a national reference for United States multiple myeloma patients (2019) (9)
- Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between GDP/Capita, Access to Cancer Drugs, Patient Visits to the IMF Website and Mortality-to-Incidence Ratio as Proxy for Survival (2019) (8)
- Experimental approaches to drug testing and clonogenic growth: results in multiple myeloma and acute myelogenous leukemia. (1984) (8)
- Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry. (2017) (8)
- Is magnitude of initial response predictive for survival in multiple myeloma? (1991) (8)
- Clinical staging and new therapeutic approaches in multiple myeloma. (1978) (8)
- Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. (2019) (8)
- [OKT-8+ suppressor T-lymphocytes are increased in patients with stable multiple myeloma]. (1983) (8)
- Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM) (2015) (8)
- Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay. (1985) (7)
- High-risk thyroid cancer. Prolonged survival with early multimodality therapy. (1981) (7)
- Risk of multiple myeloma in a case–spouse study (2016) (7)
- Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN) (2015) (7)
- Eliminating the complete response penalty from myeloma response criteria. (2008) (7)
- Deep Vein Thrombosis in Myeloma: Estimate of Prevelance and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG). (2006) (7)
- RT-PCR amplicons in the plasma of multiple myeloma patients--clinical relevance and molecular pathology. (2000) (7)
- Generation time (GT) of human bone marrow cells cultured in the CFC‐gm assay (1986) (7)
- SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM). (2014) (7)
- Cell kinetic analysis of human tumor stem cells. (1980) (6)
- Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma. (2009) (6)
- Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry (2016) (6)
- Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network (2019) (6)
- Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. (2021) (6)
- Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (2021) (6)
- SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM) (2014) (6)
- Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients. (2008) (6)
- ESAs not the culprit: More studies required (2008) (6)
- Impact of Novel Treatments on Multiple Myeloma Survival (2014) (6)
- Therapeutic strategies in multiple myeloma. (1980) (6)
- A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. (2007) (5)
- Danazol in hemophilia. (1984) (5)
- Multiple Myeloma: What's New (2001) (5)
- Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) (2011) (5)
- Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma. (1975) (5)
- Familial Cancer: How to Successfully Recruit Families for Germline Mutations Studies? Multiple Myeloma as an Example. (2019) (5)
- Chemotherapy of multiple myeloma. (1991) (5)
- SWOG 0204; Phase 2 Trial of Thalidomide (T) + Dexamethasone (D) Induction Followed by Tandem Autotransplant (TAT) and Prednisone (P) + T Maintenance for Multiple Myeloma (MM). (2005) (5)
- Failure of indium 111-labeled bleomycin tumor scanning to predict response to bleomycin (NSC-125066) treatment. (1974) (5)
- Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (2021) (5)
- Impact of novel therapies on multiple myeloma survival in the US: Current and future outcomes. (2015) (5)
- Treatment Patterns From 2009-2015 in Patients With Newly Diagnosed Multiple Myeloma in the United States: A Report From the Connect® MM Registry (2017) (5)
- Proliferative characteristics and sister chromatid exchange (SCE) of colony-forming cells (CFU-S) in acute myelogenous leukemia. (1985) (5)
- Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study (2021) (5)
- Characterization of rare germline variants in familial multiple myeloma (2020) (5)
- Awareness, concern, and communication between physicians and patients on bone health in cancer (2014) (5)
- Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma (2016) (5)
- Outcomes of patients with t(11;14) multiple myeloma: An International Myeloma Working Group (IMWG) multicenter study. (2019) (5)
- Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma (2021) (5)
- Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry (2019) (4)
- Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study. (2010) (4)
- Danazol-induced factor VIII and IX bypassing activity in hemophiliacs. (1985) (4)
- Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM (2010) (4)
- IMMUNOLOGICAL RECONSTITUTION IN SEVERE COMBINED IMMUNODEFICIENCY DISEASE WITH TRANSPLANTATION FROM A NON-COMPATIBLE DONOR (1974) (4)
- Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study (2021) (4)
- Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study. (1977) (4)
- Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide by H Prince, Brad Schenkel and Linda Mileshkin (2007) (4)
- Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study (2022) (4)
- B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients (2021) (4)
- Therapy of acute leukemia. (1974) (3)
- Myeloma therapy: 25 years forward--immune modulation then and now. (2008) (3)
- Crossover confusion: MPT still best. (2008) (3)
- Re: Cell and molecular biology of simian virus 40: implications for human infections and disease. (1999) (3)
- Mutational Characterisation and Tracking Disease Progression Using Circulating Cell-Free Tumor DNA in Multiple Myeloma Patients (2016) (3)
- Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study (2015) (3)
- Workshop on growth factors. (1991) (3)
- Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B: A Multicenter Retrospective Study (2016) (3)
- A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study (2013) (3)
- Epidemiology of Multiple Myeloma and Related Disease (2004) (3)
- Impact of Novel Therapies on Multiple Myeloma Survival– Current and Future Outcomes (2015) (3)
- Characterization of Patients with Multiple Myeloma in Long- Term Remission (2018) (3)
- A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma (2014) (3)
- Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry (2020) (3)
- The Genetic Contribution to the Aetiology of Thalidomide Associated VTE. (2006) (3)
- Health-Related Quality of Life Assessments Predict Relapse or Death in Patients with Newly Diagnosed Multiple Myeloma (MM): Results from the Connect® MM Registry (2018) (2)
- Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease (2014) (2)
- A new basis for treatment of multiple myeloma. (1978) (2)
- Oncology nurses take the lead in providing novel therapy guidelines for multiple myeloma. (2008) (2)
- Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients. (2009) (2)
- Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect® MM Registry (2018) (2)
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
- A multinational observational study in multiple myeloma (preamble): initial results of treatment patterns (2014) (2)
- Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect® MM Registry (2019) (2)
- The Bone Marrow Microenvironment of Multiple Myeloma Long-Term Survivors at Single Cell Resolution (2020) (2)
- Analysis of the Availability of Anti-Myeloma Drugs and Impact on the Current Management of Myeloma in Latin American Countries (2017) (2)
- Identification of Single Nucleotide Polymorphism Interactions Associated with Survival and Risk In Multiple Myeloma Using Novel Data Mining Methods (2010) (2)
- Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect ® Multiple Myeloma (MM) Disease Registry (2021) (2)
- Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine. (1981) (2)
- Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations (2009) (2)
- Connect MM: The multiple myeloma (MM) disease registry—Incidence of second primary malignancies (SPM). (2012) (2)
- Phase II evaluation of bisantrene in refractory multiple myeloma (1991) (2)
- Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry. (2019) (2)
- Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures. (2007) (2)
- Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data. (2011) (2)
- Multidisciplinary management of carcinoma of the thyroid. (1980) (2)
- Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM) (2014) (2)
- Treatment Patterns and Associated Outcomes in Patients with Relapsed or Refractory Multiple Myeloma in the US and Non-US Countries: Findings from Preamble (2017) (2)
- Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial (2022) (2)
- Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry. (2017) (2)
- Monitoring of Circulating Tumor Plasma Cells in Patients with Precursor Conditions of Multiple Myeloma: Data from the Prospective Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (2021) (2)
- SNP Associations with Event Free Survival in Myeloma from Two Phase III Clinical Trials Using the Bank On A Cure Chip. (2006) (2)
- Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study. (1991) (2)
- Early mortality (EM) for newly diagnosed multiple myeloma (NDMM) in the Connect MM U.S. registry. (2013) (2)
- Effect of leukocyte interferons on cell proliferation of human tumors in vitro. (1984) (2)
- PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA (2019) (2)
- B101 Quantification of Polymerising Serum Free Light Chains (2009) (2)
- Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients (2011) (1)
- Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study. (2012) (1)
- Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC) (2018) (1)
- Poorer Survival in Multiple Myeloma Correlates with Patients’ Age and Is Linked to a Higher Stage at Presentation but Prognostic Parameters Reflecting the Biology of the Myeloma Clone Are Not Associated with Age. (2004) (1)
- EFFECT OF DANAZOL ON APTT, COAGULANT FACTOR ACTIVITY AND BLEEDING IN HEMOPHILIA (1984) (1)
- Estimating Selection Bias in Previous Monoclonal Gammopathy of Undetermined Significance Research - the Importance of Screening: Results from the Population-Based Screening Study Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM) (2021) (1)
- Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304. (2018) (1)
- Race- and health-related quality of life among patients newly diagnosed with multiple myeloma. (2012) (1)
- Denosumab Compared with Zoledronic Acid for Preventing Skeletal Complications in Patients with Multiple Myeloma: A Randomized, Phase 3, Double-Blind, Double-Dummy Trial (2012) (1)
- Changes in patient-reported outcomes in patients diagnosed with and treated for multiple myeloma in the Connect MM registry. (2013) (1)
- An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival (2015) (1)
- Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma (2018) (1)
- Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study (2022) (1)
- Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report (2021) (1)
- Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma (2015) (1)
- ESAs not the culprit : More studies required. Authors' reply (2008) (1)
- Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma. (2009) (1)
- Evaluation and Treatment of Multiple Myeloma and Related Disorders1 (1975) (1)
- criteria Eliminating the complete response penalty from myeloma response (2009) (1)
- Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN) (2020) (1)
- Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (2022) (1)
- Characteristics, Treatment Patterns, and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in North America (NA) and Europe: Findings from the PREAMBLE Study: MM‐263 (2018) (1)
- A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma. (2014) (1)
- Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do (2022) (1)
- Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry. (2018) (1)
- Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC). (1986) (1)
- Total costs of therapy with lenalidomide or bortezomib in relapsed/refractory multiple myeloma (rrMM). (2012) (1)
- The role of imaging in multiple myeloma (2004) (1)
- Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage (2011) (1)
- Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study (2019) (1)
- WHOLE BODY FLUORO-DEOXYGLUCOSE (FDG) SCANNING IN MULTIPLE MYELOMA (MM). (1999) (1)
- Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN) (2016) (1)
- Beta 2-microglobulin: a potentially useful marker for hematologic malignancies. (1981) (1)
- Marrow transplantation for acute nonlymphoblastic leukemia. (1980) (1)
- Multiple Myeloma Profile In Latin America: Clinical and Epidemiological Observational Study (2013) (1)
- Alternating Combination Chemotherapy and Levamisole Improves Survival in Multiple Myeloma (2016) (1)
- Treatment of patients with refractory myelogenous leukemia with BCOMM [1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)] (1982) (1)
- A multinational observational study in multiple myeloma (preamble): assessment of disease impact on work productivity and activity (2014) (1)
- Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry. (2018) (1)
- Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) (2019) (1)
- Lenalidomide and Low-dose Dexamethasone for Treatment of Relapsed/Refractory Multiple Myeloma: Real-world Treatment Patterns from the PREAMBLE Study (2017) (1)
- Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study (2012) (1)
- SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure. (2005) (1)
- Large Scale Evaluation of Genetic Variation and the Risk of Multiple Myeloma. (2008) (1)
- Variation In Health-Related Quality of Life (HRQOL) by ISS Stage and ECOG Status Among Multiple Myeloma Patients. (2010) (1)
- Hematological malignancies the plasma cell disorders (1989) (1)
- Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial. (2015) (1)
- Gene Expression Profiling of Bulk CD138+ Plasma Cells in Preneoplastic Gammopathy/Asymptomatic Myeloma Identifies Distinct Subsets of Patients. (2005) (1)
- Frequency of and Associations Amongst Baseline Cytogenetics in Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry (2019) (1)
- Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry (2020) (1)
- Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016) (2017) (1)
- effusions: evidence for sequential in vivo clonal change Establishment of two new myeloma cell lines from bilateral pleural (2008) (0)
- Genetic Polymorphisms Associated with Clinical Outcome in the Intergroup Trial S9321, Comparing High Dose Therapy with Standard Dose Therapy for Myelomaon, on Behalf of ECOG, SWOG, CALGB, and the Bank on a Cure. (2004) (0)
- Myeloma and related disorders. (1994) (0)
- Chemotherapy of myeloma: Southwest Oncology Group studies. (1988) (0)
- In the Protein's Dna Contact Regions That 2998 1 5 O C T O B E R 2 0 0 8 I V O L U M E 1 1 2 , N U M B E R 8 Blood (2008) (0)
- The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) (2019) (0)
- patients from the International Myeloma Working Group favorable features and shows better survival: an analysis of 10 549 Myeloma in patients younger than age 50 years presents with more (2008) (0)
- Beyond medicines’ barriers: exploring the true cost of multiple myeloma (2022) (0)
- Contents, Vol. 78, 1987 (1987) (0)
- International grand round. Myeloma Grand Round (2001) (0)
- Multiple myeloma gammopathies A high-risk , Double-Hit , group of newly diagnosed myeloma identi fi ed by genomic analysis (2018) (0)
- PCN16 Design and Rationale of the Multiple Myeloma Preamble Study: A Prospective, Non-Interventional, Multi-Center Cohort Study (2012) (0)
- Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies (2019) (0)
- Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group (2016) (0)
- Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening. (2023) (0)
- Immunofluorescence method improves clinical utility of myeloma cell labeling indices. (1987) (0)
- Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect® MM Patient Registry (2017) (0)
- PCN142 Patient and Caregiver Preferences in Treatment Decision Making in Multiple Myeloma — Results of a Targeted Literature Review (2021) (0)
- Personalized Genetic Monitoring of myeloma using analytic multivariate analysis of total Fully-Sequenced Circulating DNA (2008) (0)
- Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy. (2005) (0)
- 1553TiPCOMPARISON OF DENOSUMAB VS ZOLEDRONIC ACID FOR TREATMENT OF BONE DISEASE IN ADULTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A RANDOMIZED, DOUBLE-BLIND, MULTINATIONAL PHASE 3 TRIAL. (2014) (0)
- Current trends in malignant melanoma. (1976) (0)
- Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM) (2021) (0)
- Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project (2018) (0)
- Prospective Comparison Study of Prognostic Value of MRD Detected By 8-Color MFC (EuroFlow-NGF) and NGS in Patients with Multiple Myeloma in ASCT Setting (2021) (0)
- In Vitro Phase II Trial of Vinca Alkaloids1 (1981) (0)
- Systematic literature review of health economic models developed for multiple myeloma to support future analyses. (2022) (0)
- Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study (2018) (0)
- Measurement of generation time (GT) and sister chromatid exchange (SCE) in human leukemic colony forming cells (LCFUs) (1982) (0)
- Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib (2022) (0)
- Current and Potential Applications for Erythropoietin: Based on communications presented at the 11th Meeting of the International Society of Haematology, European and African Division, Basel, September 1991 (1992) (0)
- Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study (2022) (0)
- Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma (2008) (0)
- DEVELOPMENT OF PERIPHERAL NEUROPATHY IN MULTIPLE MYELOMA PATIENTS; INCIDENCE, MOLECULAR CHARACTERIZATION AND EFFECT ON RESPONSE IN BORTEZOMIB VS CONVENTIONAL TREATMENT (2010) (0)
- PCN142 Association of Health-Related Quality of Life Among Patients With Multiple Myeloma With Insurance Coverage (2012) (0)
- P-195: Lenalidomide, bortezomib, and dexamethasone (RVd) as first-line (1L) therapy in patients who are non-transplanted: results from the Connect® MM registry (2022) (0)
- Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry. (2018) (0)
- Effect of t(11;14) on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry (2019) (0)
- Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN) (2020) (0)
- Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure. (2005) (0)
- Abstract 3373: Circulating tumour DNA mutations correlate with relapse in a phase II trial of bortezomib-primary refractory multiple myeloma patients receiving salvage therapy (2022) (0)
- Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study (2022) (0)
- Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry (2022) (0)
- High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia. (1987) (0)
- Real-World Utilization of Radiation Therapy (RT) in Multiple Myeloma (MM): An Analysis of the Connect® MM Registry (2022) (0)
- Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry (2017) (0)
- Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma (2022) (0)
- Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort (2022) (0)
- DANAZOL-INDUCED FACTOR IX AND VIII BYPASSING ACTIVITY (1984) (0)
- An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy (2016) (0)
- Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study (2020) (0)
- LACK OF REVERSAL WITH VERAPAMIL OF DRUG RESISTANCE IN MULTIPLE MYELOMA (1990) (0)
- Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry (2013) (0)
- INVITRO CHEMOSENSITIVITIES OF HUMAN-TUMOR STEM-CELLS TO THE PHASE-II DRUG 4'-(9- ACRIDINYLAMINO)METHANESULFON-M-ANISIDIDE AND PROSPECTIVE INVIVO CORRELATIONS (2006) (0)
- Contents, Vol. 44, 1987 (1981) (0)
- PF555 PROGNOSTIC VALUE OF NEXT GENERATION FLOW MONITORING CIRCULATING TUMOR PLASMA CELLS IN PERIPHERAL BLOOD ON MYELOMA PATIENTS AFTER TREATMENT (2019) (0)
- Characterization of rare germline variants in familial multiple myeloma (2021) (0)
- Carfilzomib, Thalidomide and Dexamethasone (KTd) is safe and effective in RRMM: interim analysis of the single arm, multicentre phase II ALLG MM018/AMN002 study (2019) (0)
- Investigation of Rare Non-Coding Variants in Familial Multiple Myeloma (2022) (0)
- Circulating tumor DNA analysis and association with relapse in patients with primary refractory multiple myeloma receiving secondary salvage therapy. (2022) (0)
- PCN141 Systematic Literature Review of Health Economic Models Developed for Myeloma (2021) (0)
- Overall survival in newly diagnosed MM patients with del(17p): A report from the Connect MM Registry. (2015) (0)
- Change In Patient-Reported Outcomes During The First Year Post-Diagnosis Of Multiple Myeloma (2013) (0)
- Treatment outcomes and healthcare resource utilization (HRU) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with lenalidomide (LEN) only or no maintenance: Connect MM registry. (2017) (0)
- Novel Approaches to Myeloma Therapy: The Role of Newer Anthracycline-Containing Regimens (2007) (0)
- Development of a Panel of 3,500 SNP Based Functional Genetic Variants Relevant to the Etiology and Outcome in Multiple Myeloma. (2005) (0)
- Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry (2022) (0)
- Original article Total cost comparison in relapsed/refractory multiple myeloma (2013) (0)
- Erratum: Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM (Blood Advances (2018) 2:13 (1608-1615) DOI: 10.1182/bloodadvances.2018017186) (2020) (0)
- Transforming growth factor-(J (TGF-(J) and negative growth control, with special relevance to leukaemia and lymphoma (1991) (0)
- Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group (2018) (0)
- P-136: Health-related quality of life (HRQL) among real-world Ide-Cel–eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry (2021) (0)
- PF564 OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY (2019) (0)
- P963: EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT (2022) (0)
- Immunologic Aspects of the Hematologic Neoplasms. (1973) (0)
- Patient and Caregiver Experience Decision Factors in Treatment Decision Making-Results of a Systematic Literature Review of Multiple Myeloma Decision Aids. (2022) (0)
- INTERNATIONAL MYELOMA FOUNDATION IV Annual Robert A. Kyle Lifetime Achievement Award Dinner Honoring (2006) (0)
- Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies (2023) (0)
- Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort (2022) (0)
- Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study (2022) (0)
- Reply to J.C. Regelink et al (2010) (0)
- An integrated pharmacogenomic strategy for the definition of thalidomide response signatures in presenting cases of multiple myeloma (2007) (0)
- 1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma (2018) (0)
- Abstract 782: Circulating tumour DNA-based molecular response predicts treatment outcome in multiple myeloma (2023) (0)
- Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study (2018) (0)
- Prospective Investigation of Genetic Alterations in Osteolytic Lesions Compared to Paired Random Aspirates (2016) (0)
- The Role of Anatomic and Functional Imaging in Myeloma (2008) (0)
- and kinetic features immunochemical, immunophenotypic, genotypic, cytologic, cell culture, Delineation of a novel pre-B cell component in plasma cell myeloma: (2011) (0)
- powerful myeloma staging system C-reactive protein and beta-2 microglobulin produce a simple and (2013) (0)
- Multiple Myeloma (1992) (0)
- Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (2022) (0)
- Author / Subject Indexes (2004) (0)
- OAB-037: Detection of abnormal plasma cells by multiparameter flow cytometry in a screened cohort of patients with monoclonal gammopathy of undetermined significance (2022) (0)
- PS1384 TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY (2019) (0)
- Modulation of myeloma growth by lymphokines and accessory cells (1987) (0)
- Prevalence of smoldering multiple myeloma based on nationwide screening (2023) (0)
- Circulating Nucleic Acids in Multiple Myeloma: Presence of Non-Coding/ Intergenic DNA Reflects Disease Activity. (2005) (0)
- Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry. (2020) (0)
- Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry. (2022) (0)
- autologous stem cell transplantation treatment of multiple myeloma patients who are candidates for International Myeloma Working Group consensus approach to the (2012) (0)
- Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting (2021) (0)
- Inherited Genetic Variation and the Risk of Developing Venous Thrombosis with Thalidomide Treatment in Myeloma Patients. (2005) (0)
- Subject Index, Vol. 78, 1987 (1987) (0)
- Treatment of refractory acute myelogenous leukemia (AML) with vincristine, high dose methotrexate, 1,3-bis-(2-chlorethyl)-1-nitrosourea (BCNU), cyclophosphamide, and methyl-glyoxal bis-guanylhydrazone (MGBG) (1981) (0)
- Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect® MMpatient Registry (2017) (0)
- Concise of the Disease and Treatment Options (2015) (0)
- Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age (2022) (0)
- New US Myeloma Registry (Connect MM® – The Multiple Myeloma Disease Registry): Features of Newly Diagnosed Patients In 2010 (2010) (0)
- New Bioaccumulations of Toxins in Resident Coastal Dolphins Signal Dangers of Human Myeloma. (2006) (0)
- Pharmacokinetics of 14C putrescine and 14C spermidine in patients with cancer (1977) (0)
- GENETIC VARIATIONS ASSOCIATED WITH TREATMENT RESPONSE, PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA IN THE HOVON 50/GMMG-HD3 TRIALS (2010) (0)
- Assessment of current practices among physicians and awareness and concern among patients for bone health in cancer. (2011) (0)
- A222 Survival and Years of Life Lost in Different Age Categories of Patients with Multiple Myeloma (2009) (0)
- Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study (2022) (0)
- US Cooperative Group Trials (2009) (0)
- Multiple myeloma update : new advances in biology and treatment (2001) (0)
- Idiopathic thrombocytopenic purpura (ITP) in pregnancy. (1984) (0)
- PCN117 ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ISS STAGE AND ECOG STATUS IN MULTIPLE MYELOMA (2011) (0)
- Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma (2021) (0)
- report of the International Myeloma Workshop Consensus Panel 2 Consensus recommendations for risk stratification in multiple myeloma (2011) (0)
- Development of Bortezomib Induced Peripheral Neuropathy (BiPN) In Multiple Myeloma : Incidence and Molecular Characterization In Newly Diagnosed Patients Treated with Bortezomib (2010) (0)
- P-229: Real-world outcomes of sequencing elotuzumab (elo)-based regimens following daratumumab (dara) in patients with relapsed/refractory multiple myeloma: results from the Connect® MM Registry (2022) (0)
- Syddansk Universitet Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma a study of the International Myeloma Working (2017) (0)
- Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years. (2005) (0)
- SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure. (2005) (0)
- Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia, (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Brian G. M. Durie?
Brian G. M. Durie is affiliated with the following schools:
